These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30217763)

  • 1. Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study.
    Woldu SL; Matulay JT; Clinton TN; Singla N; Freifeld Y; Sanli O; Krabbe LM; Hutchinson RC; Lotan Y; Hammers H; Hannan R; Brugarolas J; Bagrodia A; Margulis V
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1221-e1235. PubMed ID: 30217763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
    Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
    Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
    Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
    Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
    World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes after cytoreductive nephrectomy and thrombectomy of patients with metastatic renal cell carcinoma with venous tumor thrombus: a retrospective study from a large Chinese center.
    Chen K; Liu Z; Li Y; Zhao X; Zhang Y; Bi H; Wang G; Liu C; Tian X; Zhang H; Ma L; Zhang S
    World J Surg Oncol; 2023 Jun; 21(1):170. PubMed ID: 37280590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
    Alhalabi O; Karam JA; Tannir NM
    Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.
    Ha FJ; Spain L; Dowling A; Kwan EM; Pezaro C; Day D; Chia PL; Tran B; Pook D; Weickhardt AJ
    Asia Pac J Clin Oncol; 2019 Oct; 15(5):e97-e102. PubMed ID: 30701671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
    Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
    Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach.
    Hall ME; Bhindi B; Luckenbaugh AN; Laviana AA; Moses KA; Satkunasivam R; Rini B; Klaassen Z; Wallis CJD
    Cancer Causes Control; 2021 Jul; 32(7):675-680. PubMed ID: 33963938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
    Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
    World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database.
    Singla N; Hutchinson RC; Ghandour RA; Freifeld Y; Fang D; Sagalowsky AI; Lotan Y; Bagrodia A; Margulis V; Hammers HJ; Woldu SL
    Urol Oncol; 2020 Jun; 38(6):604.e9-604.e17. PubMed ID: 32253116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
    de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
    Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy.
    Kim SH; Kim JK; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
    Oncotarget; 2017 Jul; 8(30):49615-49624. PubMed ID: 28548948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
    Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
    Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
    Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
    Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.
    Goebell PJ; Staehler M; Müller L; Nusch A; Scheffler M; Sauer A; von Verschuer U; Tech S; Kruggel L; Jänicke M; Marschner N;
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1101-e1115. PubMed ID: 30061035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.
    Hanna N; Sun M; Meyer CP; Nguyen PL; Pal SK; Chang SL; de Velasco G; Trinh QD; Choueiri TK
    J Clin Oncol; 2016 Sep; 34(27):3267-75. PubMed ID: 27325852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
    Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
    Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.